Drugs /

dl-selenomethionine

Back to Drugs List

Overview

NCI Definition [1]:
A selenium (Se) analogue of methionine in which sulfur is replaced with the trace element selenium. Selenomethionine (SeMet) can incorporate into proteins in place of methionine with no effects on protein structure and function, providing a mechanism for reversible Se storage in organs and tissues. Free selenium is incorporated into selenocysteine, an amino acid found in more than thirty selenoproteins including the glutathione peroxidases (GPx) enzymes, thioredoxin reductase (TR) and the iodothyronine deiodinase enzymes.

Clinical Trials

View Clinical Trials for dl-selenomethionine

Dl-selenomethionine has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dl-selenomethionine, 1 is phase 1/phase 2 (1 open).

Clear cell renal cell carcinoma is the most common disease being investigated in dl-selenomethionine clinical trials [2].

Drug Details

Synonyms [2]:
butanoic acid, 2-amino-4-(methylseleno)-, selenomethionine, selenomethionine, selenomethionine (substance), dl-selenomethionine, butanoic acid, 2-amino-4-(methylseleno)-, selenomethionine, selenomethionine [chemical/ingredient], selenomethionine, dl-, selenium methionine
NCIT ID [1]:
C826
SNOMED ID [1]:
F-D5C15

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.